Inhibitors of glucose transporters, PKM-2 and LDH-A, attenuate aerobic glycolysis and tumor proliferation with the potential therapeutic role [46], alone or in combination with anti-angiogenic [47] and immune checkpoint [48] therapies. This evidence concerns the gene LDHA and neoplasm.